<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080571</url>
  </required_header>
  <id_info>
    <org_study_id>PGIMER RADIOLOGY</org_study_id>
    <nct_id>NCT03080571</nct_id>
  </id_info>
  <brief_title>Intraarterial Stem Cells in Subacute Ischemic Stroke</brief_title>
  <official_title>To Evaluate the Safety, Feasibility and Clinical Outcome of Intraarterial Infusion of Bone Marrow Derived Mononuclear Cells in Subacute Ischaemic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is a leading cause of morbidity and mortality.Acute ischemia causes irreversible
      damage to neurons and glial cells, leading to functional deficits and chronic sequelae with
      variable degrees of spontaneous recovery of function. Stem cells have been shown to enhance
      recovery through multiple immunomodulatory effects, neoangiogenesis and neurogenesis.

      We conducted a prospective randomised end observer blinded study to evaluate primarily the
      safety of intraarterial autologous stem cells delivered to ipsilateral middle cerebral artery
      in acute and subacute stroke patients (0-15 days post ictus).Secondarily we aimed to evaluate
      the outcome on the basis of clinical evaluation and follow up imaging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. This study was done over a period of one and a half years from July 2015 to December
           2016. A total of 229 patients who presented with acute middle cerebral artery stroke and
           admitted at Post graduate institute of medical education and research were evaluated for
           recruitment into this study.

        2. Participants who satisfied the inclusion criteria were randomized at 1 week into control
           and stem cell infusion test group within 15 days of stroke onset.

        3. Investigators evaluated 20 patients, with 10 each in control and stem cell infusion test
           group.

        4. Participants in the test group were infused autologous bone marrow mononuclear cells
           through intraarterial route using a microcatheter which was placed in proximal
           ipsilateral M1 segment of MCA. Participants in the control group did not receive stem
           cell therapy. Rest of the pharmacological treatment and physiotherapy were similar in
           both groups for the period of 6 months.

      5,Participants were evaluated with clinical and radiological follow up at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>test group :Stem cell plus standard care control group : standard care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in National Institutes of Health Stroke Scale</measure>
    <time_frame>6 month</time_frame>
    <description>increase in National Institutes of Health Stroke Scale more than / equal to 4 points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>symptomatic intracranial hemorrhage</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>new ischemic lesion</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified rankin score</measure>
    <time_frame>6 months</time_frame>
    <description>A modified rankin score of 0-1 in patients with National Institutes of Health Stroke Scale of 8-14 at the admission and modified rankin score of 0-2 in patients with National Institutes of Health Stroke Scale &gt;14 at the admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>MCA Infarction</condition>
  <arm_group>
    <arm_group_label>Stem cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous BMMNC stem cells with standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised in this group received standard care only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous BMMNC stem cells</intervention_name>
    <description>Autologous BMMNC injected in the ipsilateral MCA</description>
    <arm_group_label>Stem cell group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <arm_group_label>Stem cell group</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Requires presence of all of the following

          1. Age range 20-80 years symptoms

          2. Signs of clinically definite MCA stroke (0 to 14 days post ictus)

          3. National Institute of Health Stroke Scale (NIHSS)&gt; 7,

          4. Stroke clinically and on imaging conforming to the MCA territory,

          5. Recanalization/patency of involved M1 segment of MCA on imaging

          6. Patency of carotid arteries for intra-arterial access of cerebral circulation

        Exclusion Criteria: Requires presence of any of the following

          1. cerebral hemorrhage on CT/MRI

          2. Imaging evidence of M1-MCA segment complete occlusion

          3. Hemodynamic instability

          4. Known defect of clotting or platelet function

          5. Severe co-morbidity precluding intra-arterial intervention

          6. Hepatic or renal dysfunction

          7. Pregnant patients

          8. Patient likely to be unavailable for follow-up

          9. Patients with evidence of chronic illness or advanced cancer

         10. Patient already dependent in activities of daily living before the present acute
             stroke i.e. pre stroke mRS &gt;3

         11. Refusal to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Gupta, DM</last_name>
    <role>Study Director</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vikas Bhatia, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <reference>
    <citation>Moniche F, Gonzalez A, Gonzalez-Marcos JR, Carmona M, Piñero P, Espigado I, Garcia-Solis D, Cayuela A, Montaner J, Boada C, Rosell A, Jimenez MD, Mayol A, Gil-Peralta A. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012 Aug;43(8):2242-4. doi: 10.1161/STROKEAHA.112.659409. Epub 2012 Jul 3.</citation>
    <PMID>22764211</PMID>
  </reference>
  <reference>
    <citation>Battistella V, de Freitas GR, da Fonseca LM, Mercante D, Gutfilen B, Goldenberg RC, Dias JV, Kasai-Brunswick TH, Wajnberg E, Rosado-de-Castro PH, Alves-Leon SV, Mendez-Otero R, Andre C. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011 Jan;6(1):45-52. doi: 10.2217/rme.10.97.</citation>
    <PMID>21175286</PMID>
  </reference>
  <reference>
    <citation>Suárez-Monteagudo C, Hernández-Ramírez P, Alvarez-González L, García-Maeso I, de la Cuétara-Bernal K, Castillo-Díaz L, Bringas-Vega ML, Martínez-Aching G, Morales-Chacón LM, Báez-Martín MM, Sánchez-Catasús C, Carballo-Barreda M, Rodríguez-Rojas R, Gómez-Fernández L, Alberti-Amador E, Macías-Abraham C, Balea ED, Rosales LC, Del Valle Pérez L, Ferrer BB, González RM, Bergado JA. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci. 2009;27(3):151-61. doi: 10.3233/RNN-2009-0483.</citation>
    <PMID>19531871</PMID>
  </reference>
  <reference>
    <citation>Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011 Jul;70(1):59-69. doi: 10.1002/ana.22458.</citation>
    <PMID>21786299</PMID>
  </reference>
  <reference>
    <citation>Friedrich MA, Martins MP, Araújo MD, Klamt C, Vedolin L, Garicochea B, Raupp EF, Sartori El Ammar J, Machado DC, Costa JC, Nogueira RG, Rosado-de-Castro PH, Mendez-Otero R, Freitas GR. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21 Suppl 1:S13-21. doi: 10.3727/096368912X612512.</citation>
    <PMID>22507676</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Vikas Bhatia</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

